PENTIXAPHARM HOLDING N AG
Research PENTIXAPHARM HOLDING N AG (PTP) on Bullrun: market cap EUR 46.59M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPTP
- ExchangeXETRA
- CountryGermany
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 46.59M
- Financial periodQ1 2026
- RevenueEUR 0
- Net income-EUR 3.18M
- Free cash flow-EUR 2.47M
Valuation Snapshot
latest market cap is EUR 46.59M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 93.00K | -EUR 16.51M | -EUR 18.60M | -7207.5% | n/a | EUR 4.62M | n/a | EUR 35.07M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 46.59M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About PENTIXAPHARM HOLDING N AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PENTIXAPHARM HOLDING N AG's market cap?
PENTIXAPHARM HOLDING N AG's market capitalization is EUR 46.59M.
What does PENTIXAPHARM HOLDING N AG do?
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase 1/2 study; and develops diagnosis for.